Longeveron (LGVN) Stock
Clinical stage biotech developing cell therapies for aging. Here's the price, business snapshot, and what's worth knowing about Longeveron in October 2026.
Longeveron Inc (LGVN) is a clinical-stage biotechnology company with a market capitalisation of about $17.7 million, focused on developing allogeneic cell‑based therapies aimed at ageing‑related conditions and organ injury. Investors should know this is an early‑stage, science‑driven business: value is highly dependent on clinical trial outcomes, regulatory milestones and potential partnerships or licensing deals. The company typically has limited revenue and may need additional financing, which can dilute shareholders or affect the share price. Positive trial results or strategic collaborations can materially re‑rate the stock, while setbacks, trial delays or funding shortfalls can lead to sharp declines. Follow cash runway, upcoming readouts, management commentary and regulatory interactions for signals. This summary is educational only and not personal financial advice; biotech investing is high risk and volatile — values can fall as well as rise.
